Gi-Young Park

Dr. Gi-Young Park

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2017 in Ultrasonography
Verified
Journal Article
Open access
PDF file
GPGi-Young Park
Gi-Young Park
JLJin Hoon Lee
Jin Hoon Lee
Daegil KwonDaegil Kwon
Daegil Kwon
The purpose of this study was to measure the axillary recess (AR) thickness in an asymptomatic shoulder by using ultrasonography (US) and to analyze the factors affecting it. We recruited 141 patients (52 males; 89 females; age, 57.7±9.9 years) with unilateral shoulder pain and performed US on the unaffected shoulder. Two physiatrists measured the AR thickness of the unaffected shoulder independently. All patients were examined in an upright sitting position with 90° shoulder abduction. The ultrasonographic transducer was placed longitudinally on the mid-axillary line and along the long axis of the humeral shaft. The factors affecting the AR thickness values were analyzed, and intra-class correlation coefficients were used for assessing the reproducibility of each measurement. The intrarater reliability values for the two physiatrists were 0.98 and 0.96, respectively. The inter-rater reliability of the mean AR thickness measurements was 0.91. The mean AR thickness in all subjects, males, and females was 2.8±0.6 mm, 3.1±0.6 mm, and 2.6±0.5 mm (P<0.01), respectively. No difference between the left and the right sides (males, P=0.086; females, P=0.535) or between the dominant and the non-dominant sides (males, P=0.173; female, P=0.244) was found. The AR thickness correlated positively with the height (r=0.313, P<0.01) and the weight (r=0.319, P<0.01). However, it did not correlate with the body mass index (r=0.152, P=0.077) or the age (r=-0.056, P=0.515). US measurements of the AR thickness in asymptomatic shoulders demonstrated excellent intrarater and inter-rater reliabilities. The AR thickness showed anatomical variation with sex, height, and weight.

15 June 2025 in Keimyung Medical Journal
Verified
Journal Article
Open access
PDF file
GPGi-Young Park
Gi-Young Park
Byeong-Churl JangByeong-Churl Jang
Byeong-Churl Jang
Polydeoxyribonucleotide (PDRN), a highly purified salmon‑sperm–derived DNA polymer, exhibits potent regenerative and anti-inflammatory effects. This review critically explores the dual mechanisms of PDRN—namely, adenosine A2A receptor activation and nucleotide provision via the salvage pathway—and synthesizes the current clinical evidence regarding its applications in dermatology and wound healing. Preclinical and clinical studies have shown that PDRN enhances angiogenesis, modulates cytokine profiles, and accelerates tissue repair processes, resulting in improved healing rates in chronic diabetic foot ulcers, pressure ulcers, and venous leg ulcers as well as faster epithelial regeneration in surgical donor sites and corneal wounds. Adjunctive benefits have also been reported in lichen sclerosis, osteoarthritis, and aesthetic dermatology. Furthermore, PDRN demonstrates excellent safety profile, with minimal adverse events reported across multiple trials and real-world applications. Emerging delivery platforms and combination therapies have further expanded the therapeutic potential. This review highlights the potential of PDRN as a versatile and safe regenerative agent by integrating mechanistic insights with robust clinical data.

1 January 2017 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
JAJae Ki Ahn
Jae Ki Ahn
DKDong Rak Kwon
Dong Rak Kwon
GPGi-Young Park
Gi-Young Park
KLKi-Hoon Lee
Ki-Hoon Lee
JRJae Hwal Rim
Jae Hwal Rim
Daegil KwonDaegil Kwon
Daegil Kwon
Ahn JK, et al. Ann Rehabil Med. 2017 Feb;41(1):104-112. https://doi.org/10.5535/arm.2017.41.1.104

10 September 2017 in Molecules
Verified
Journal Article
Open access
PDF file
TKTae Hwan Kim
Tae Hwan Kim
Soyoung ShinSoyoung Shin
Soyoung Shin
SKSarah Kim
Sarah Kim
Jürgen B. BulittaJürgen B. Bulitta
Jürgen B. Bulitta
KWKwon Yeon Weon
Kwon Yeon Weon
Beom ShinBeom Shin
Beom Shin
Gemcitabine and erlotinib are the chemotherapeutic agents used in the treatment of various cancers and their combination is being accepted as a first-line treatment of advanced pancreatic cancer. Hyangsayukgunja-tang (HYT) is a traditional oriental medicine used in various digestive disorders and potentially helpful to treat gastrointestinal adverse effects related to chemotherapy. The present study was aimed to evaluate the effect of HYT on the pharmacokinetics of gemcitabine and erlotinib given simultaneously in rats. Rats were pretreated with HYT at an oral dose of 1200 mg/kg/day once daily for a single day or 14 consecutive days. Immediately after pretreatment with HYT, gemcitabine and erlotinib were administered by intravenous injection (10 mg/kg) and oral administration (20 mg/kg), respectively. The effects of HYT on pharmacokinetics of the two drugs were estimated by non-compartmental analysis and pharmacokinetic modeling. The pharmacokinetics of gemcitabine and erlotinib were not altered by single dose HYT pretreatment. However, the plasma levels of OSI-420 and OSI-413, active metabolites of erlotinib, were significantly decreased in the multiple dose HYT pretreatment group. The pharmacokinetic model estimated increased systemic clearances of OSI-420 and OSI-413 by multiple doses of HYT. These data suggest that HYT may affect the elimination of OSI-420 and OSI-413.

1 January 2018 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
GPGi-Young Park
Gi-Young Park
DKDong Rak Kwon
Dong Rak Kwon
Daegil KwonDaegil Kwon
Daegil Kwon
JRJae Hwal Rim
Jae Hwal Rim
Park GY, et al. Ann Rehabil Med. 2018 Feb;42(1):76-84. https://doi.org/10.5535/arm.2018.42.1.76